Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Recent Strategic Transactions and Business Developments
ROIV logo

Roivant Cashes In $1.2B Dermavant Sale, Bolsters $4.9B War Chest

ROIV10-KFiling Date: 5/29/2025
Roivant Sciences Ltd.
Description

What this story covers

Roivant Sciences' FY25 10-K highlights strategic sales like $1.2B Dermavant divestiture, yielding $373M gain and $4.9B cash reserves. Pipeline advances in immunology (brepocitinib, anti-FcRn) amid rising R&D to $550M, netting $357M loss. Vant model drives agility but faces trial and competitive risks.

Story snapshot

CompanyRoivant Sciences Ltd.
TickerROIV
VariantStandard detailed
Duration12:04
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001140361-25-020715

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in